"An aquisition down the line that might make sense would be a suitable CGMP rated manufacturing facility (in Australia) that could produce (in the future)an expanded product range using Cellestis's technology. Alternatively they could build one. "
Personally, I don't favor that idea (and I doubt that the company would).
The current methodology of having multiple contract manufacturers that compete for our business and provide natural DR and scaleability seems most sensible. Much better for CST to "stick to their knitting".
CST Price at posting:
$2.00 Sentiment: LT Buy Disclosure: Held
